Evrysdi (risdiplam) – Revmatoid Artritt

Verna: Informasjon om nyfødtscreening for spinal muskelatrofi

Roche presents its new data on the SUNFISH, JEWELFISH, RAINBOWFISH study

Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years
59% of infants were able to sit without support for at least 5 seconds
No new safety signals were identified
In August, the FDA approved Evrysdi for the treatment of SMA in adults and children 2 months and older
Read more